TrialHaemophilia : the official journal of the World Federation of Hemophilia2022

Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.

Yaming Xi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.